- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05638126
Safety and Tolerance of Increased Doses of HRS-1780 Tablets in Healthy Subjects
October 23, 2023 updated by: Shandong Suncadia Medicine Co., Ltd.
A Phase I Single and Multiple Ascending Dose and Food Effect Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HRS-1780 Tablets in Healthy Male Subjects
This is a randomized, double-blind, placebo-controlled phase I clinical study.
The primary objective is to evaluate the safety, tolerability, PK, and PD of single- and multiple-dose HRS-1780 in healthy subjects, and to evaluate the food effect on PK of HRS-1780.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
96
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Manchen Bao, M.D
- Phone Number: 0518-82342973
- Email: manchen.bao@hengrui.com
Study Locations
-
-
Sichuan
-
Chengdu, Sichuan, China, 610044
- West China Hospital of Sichuan University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- 18-45 years old (including boundary value, whichever is at the time of signing the informed consent form), healthy male.
- Weight ≥50 kg, body mass index (BMI = body mass/height square (kg/m2)) is in the range of 18-28 (including boundary values)
- Obtain informed consent before any activity related to the experiment begins, have a full understanding of the purpose and significance of the experiment, and be willing to comply with the test plan and dietary requirements.
- Subjects (including partners) have no family planning within 3 months from the beginning of the signing of the informed consent form to the last dose, and are willing to adopt the efficient contraceptive measures stipulated in the program and guarantee not to donate sperm.
Exclusion Criteria:
- People with a history of hypertension.
- People with severe systemic infectious diseases, serious trauma or major surgical surgery before screening; those who plan to undergo surgery during the trial
- There has been a history of clinical abnormal gastric emptying and severe chronic gastrointestinal diseases.
- Diseases found to show clinical significance before screening
- Combined with diuretics before screening
- Drugs were used 2 weeks before screening.
- Laboratory or physical examination with any abnormalities and the researcher's judgment is clinically significant.
- 12-lead electrocardiogram is abnormal and of clinical significance
- Positive for hepatitis B surface antigen, positive for hepatitis C antibody, positive for syphilis spirochete antibody, positive for HIV antibody
- People with severe allergic diseases or known or suspected of being allergic to any of the ingredients in the research drug, allergic constitution (multiple drugs and food allergies)
- Participated in the clinical trial of any drug or medical device within the first 3 months of screening or planned to participate in the clinical trial of other drugs or medical devices during the trial period (subject to the signing of informed consent)
- Drink more than 14 units of alcohol per week in the first 6 months of screening; or those who have taken alcohol products 48 hours before administration; or those who have tested positive for alcohol exhalation during the baseline period.
- Smoking more than 5 cigarettes a day in the 3 months before screening or using any tobacco products 48 h before administration.
- Drink/eat coffee, tea, grapefruit, chocolate or soft drinks, such as cola containing methamphetrine (tein, caffeine or cocoaine) within 3 days before screening
- Those who have had a history of drug abuse in the past five years or have used drugs in the first three months of the trial; or urine drugs are screened positive
- Blood donation ≥ 200 mL within 1 month before screening; or blood donation ≥ 400 mL within 3 months before screening; or trauma or surgical surgery with blood donation (plasma or platelets) or blood loss of ≥ 400 mL within 2 weeks
- Inability tolerate venous puncture and blood collection or dizziness
- Subjects who believe that there are other factors that are not suitable to participate in this test
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Part 1
HRS-1780 table or placebo single dose
|
HRS-1780 table or placebo single dose
HRS-1780 table or placebo single dose with food effect
HRS-1780 table or placebo multiple dose
|
Experimental: Part 2
HRS-1780 table or placebo single dose with food effect
|
HRS-1780 table or placebo single dose
HRS-1780 table or placebo single dose with food effect
HRS-1780 table or placebo multiple dose
|
Experimental: Part 3
HRS-1780 table or placebo multiple dose
|
HRS-1780 table or placebo single dose
HRS-1780 table or placebo single dose with food effect
HRS-1780 table or placebo multiple dose
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Assess the incidence and severity of adverse events in healthy subjects after single and multiple doses of HRS-1780 tablets
Time Frame: About a month from the first medication to the evaluation.
|
About a month from the first medication to the evaluation.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Assess the concentration of HRS-1780 in plasma and urine
Time Frame: About 4 weeks after the first dose
|
About 4 weeks after the first dose
|
Evaluation of AUC0-t of HRS-1780 in plasma and urine
Time Frame: About 4 weeks after the first dose
|
About 4 weeks after the first dose
|
Evaluation of AUC0-∞ of HRS-1780 in plasma and urine
Time Frame: About 4 weeks after the first dose
|
About 4 weeks after the first dose
|
Evaluation of Tmax of HRS-1780 in plasma and urine
Time Frame: About 4 weeks after the first dose
|
About 4 weeks after the first dose
|
Evaluation of Cmax of HRS-1780 in plasma and urine
Time Frame: About 4 weeks after the first dose
|
About 4 weeks after the first dose
|
Evaluation of t1/2 of HRS-1780 in plasma and urine
Time Frame: About 4 weeks after the first dose
|
About 4 weeks after the first dose
|
Evaluate the blood pressure of subjects over time after HRS-1780 administration
Time Frame: About 4 weeks after the first dose
|
About 4 weeks after the first dose
|
Evaluate the heart rate of subjects over time after HRS-1780 administration
Time Frame: About 4 weeks after the first dose
|
About 4 weeks after the first dose
|
Evaluate the concentrations of plasma renin activity of subjects over time after HRS-1780 administration
Time Frame: About 4 weeks after the first dose
|
About 4 weeks after the first dose
|
Evaluate the plasma aldosterone of subjects over time after HRS-1780 administration
Time Frame: About 4 weeks after the first dose
|
About 4 weeks after the first dose
|
Evaluate the plasma angiotensin II of subjects over time after HRS-1780 administration
Time Frame: About 4 weeks after the first dose
|
About 4 weeks after the first dose
|
Evaluate the urinary creatinine curve of subjects with time after HRS-1780 administration
Time Frame: About 4 weeks after the first dose
|
About 4 weeks after the first dose
|
Evaluate the change curve of urine creatinine over time relative to baseline in subjects after HRS-1780 administration
Time Frame: About 4 weeks after the first dose
|
About 4 weeks after the first dose
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 2, 2023
Primary Completion (Estimated)
December 1, 2023
Study Completion (Estimated)
December 1, 2023
Study Registration Dates
First Submitted
November 24, 2022
First Submitted That Met QC Criteria
December 5, 2022
First Posted (Actual)
December 6, 2022
Study Record Updates
Last Update Posted (Actual)
October 25, 2023
Last Update Submitted That Met QC Criteria
October 23, 2023
Last Verified
November 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HRS-1780-101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Kidney Disease
-
3-C Institute for Social DevelopmentUniversity of North Carolina, Chapel HillCompletedChronic Kidney Diseases | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Pediatric Kidney Disease | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage V | Chronic Kidney Disease, Stage IV (Severe) | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease, Stage IUnited States
-
Universiti Putra MalaysiaRecruitingChronic Kidney Diseases | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Chronic Kidney Disease stage3 | Chronic Kidney Disease Requiring Chronic DialysisMalaysia
-
National Taiwan University HospitalCompletedChronic Kidney Disease stage4 | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease Stage 1Taiwan
-
Centre Hospitalier le MansLe Mans UniversiteWithdrawnFatigue | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage3 | Chronic Kidney Failure | Chronic Kidney Disease, Stage 4 (Severe)
-
Centre Hospitalier le MansLe Mans UniversiteRecruitingFatigue | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Chronic Kidney Disease Stage 3BFrance
-
American Academy of Family PhysiciansUniversity of Colorado, Denver; National Institute of Diabetes and Digestive... and other collaboratorsCompletedChronic Kidney Disease | Chronic Renal Insufficiency | Chronic Kidney Insufficiency | Chronic Renal Diseases | Kidney Insufficiency, ChronicUnited States
-
Lund UniversityBaxter Healthcare Corporation; Universidad de CórdobaCompletedEnd Stage Kidney Disease | Chronic Kidney Disease Requiring Chronic DialysisArgentina
-
Centre Hospitalier Saint Joseph Saint Luc de LyonNot yet recruitingKidney Failure, Chronic | Diet Habit | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage 3B | Chronic Kidney Disease, Stage 3 (Moderate) | Chronic Kidney Disease Stage 3A (Disorder)France
-
A.C. AbrahamsCompletedEnd Stage Renal Disease | Chronic Kidney Disease | End Stage Kidney Disease | Chronic Kidney FailureNetherlands
-
Far Eastern Memorial HospitalActive, not recruitingMetabolic Syndrome | Chronic Disease | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease Stage 3 | Chronic Kidney Disease Stage 4 | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease Stage 1Taiwan
Clinical Trials on HRS-1780 table or placebo
-
Shandong Suncadia Medicine Co., Ltd.Not yet recruiting
-
Shandong Suncadia Medicine Co., Ltd.Not yet recruiting
-
Shandong Suncadia Medicine Co., Ltd.Not yet recruitingOverweight and Obesity
-
Guangdong Hengrui Pharmaceutical Co., LtdEnrolling by invitationRefractory Chronic CoughChina
-
Shandong Suncadia Medicine Co., Ltd.RecruitingObstructive Hypertrophic CardiomyopathyChina
-
Shandong Suncadia Medicine Co., Ltd.Not yet recruiting
-
Fujian Shengdi Pharmaceutical Co., Ltd.Not yet recruitingCerebral Stroke
-
Chengdu Suncadia Medicine Co., Ltd.RecruitingGlomerulonephritisChina
-
Guangdong Hengrui Pharmaceutical Co., LtdCompleted
-
Atridia Pty Ltd.CompletedInflammatory Bowel DiseaseAustralia